Lykos Therapeutics (MDMA-AT developer) will either cease operations, be acquired, or publicly announce a pivot away from MDMA-PTSD as primary program before December 31, 2026.

Lykos Therapeutics (the company developing MDMA for PTSD) already received a rejection from the FDA in August 2024 and fired 75% of its staff. Fixing the problems requires running a brand-new Phase 3 trial that will cost $50–100 million and take 3–5 years. The company has no approved drugs, no revenue, and limited cash left. By the end of 2026, Lykos will either shut down, be bought by another company, or publicly announce they're switching away from MDMA as their main focus.

Lykos received a CRL from FDA in August 2024 and laid off ~75% of staff. A resubmission requires a new Phase 3 trial, which analysts estimate at $50-100M and 3-5 years minimum. The company has no approved products, limited cash runway post-layoffs, and faces a hostile regulatory environment. Acquisition by a larger pharma with a different indication strategy or full wind-down are the most probable outcomes. This is falsifiable: company status and pipeline are publicly disclosed via SEC filings and press releases.